222. Primary nephrotic syndrome Clinical trials / Disease details
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00135811 (ClinicalTrials.gov) | November 2004 | 24/8/2005 | Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) | Focal Segmental Glomerulosclerosis Clinical Trial | Glomerulosclerosis, Focal | Drug: Cyclosporin;Drug: MMF and Dexamethasone | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | The Cleveland Clinic | Completed | 2 Years | 40 Years | Both | 207 | Phase 3 | United States |